# A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors

> **NCT05650242** · PHASE1 · UNKNOWN · sponsor: **Shandong Boan Biotechnology Co., Ltd** · enrollment: 177 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BA1106

## Key facts

- **NCT ID:** NCT05650242
- **Lead sponsor:** Shandong Boan Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-31
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650242, "A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05650242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*